Completed PHASE2 INTERVENTIONAL 1-arm NCT00759408

The Role of Endothelin in Pulmonary Hypertension

Sponsor: Brigham and Women's Hospital

Interventions BQ-123

Updated 10 times since 2017 Last updated: Nov 1, 2018 Started: Feb 28, 1999 Primary completion: Oct 31, 2010 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pulmonary Hypertension and is currently completed. Brigham and Women's Hospital leads this study, which shows 10 recorded versions since 1999 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Dec 2018 — Jan 2021 [monthly]

Completed PHASE2
Nov 2018 — Dec 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jun 2018 — Nov 2018 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Feb 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital

Data source: Brigham and Women's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States